Cancer Genomics Clinic: From Tumor Profiling to Targeted Therapies

• Introduction
• Chapter 1 Foundations of Cancer Genomics and Precision Oncology
• Chapter 2 Specimen Acquisition and Quality: Tissue and Liquid Biopsy
• Chapter 3 Sequencing Technologies: Targeted Panels, WES, WGS, and RNA-Seq
• Chapter 4 Bioinformatics Pipelines and Quality Control for Clinical Labs
• Chapter 5 Somatic vs. Germline: Interpretation, Incidental Findings, and Counseling
• Chapter 6 Variant Classification and Actionability Frameworks for Oncology
• Chapter 7 Oncogenic Drivers and Pathways: From Discovery to Drug Targets
• Chapter 8 Resistance Mechanisms: Intrinsic, Acquired, and Bypass Signaling
• Chapter 9 Structural Variation: Copy Number, Gene Fusions, and Complex Rearrangements
• Chapter 10 Tumor Mutational Burden, Microsatellite Instability, and DNA Repair Signatures
• Chapter 11 Homologous Recombination Deficiency and PARP Inhibitor Strategies
• Chapter 12 Immuno-Oncology Biomarkers Beyond PD-L1: TILs, GEPs, and Neoantigens
• Chapter 13 Liquid Biopsy in Practice: ctDNA for Monitoring, MRD, and Relapse
• Chapter 14 Navigating Genomic Reports: From Raw Calls to Therapeutic Hypotheses
• Chapter 15 Selecting Targeted Therapies: Line of Therapy, Dosing, and Sequencing
• Chapter 16 Managing Toxicities and Drug–Drug Interactions in Targeted Agents
• Chapter 17 Clinical Trial Matching: Basket, Umbrella, and Platform Designs
• Chapter 18 Special Populations: Pediatrics, Geriatrics, and Rare Cancers
• Chapter 19 Tumor Board Playbook: Workflows, Checklists, and Deliberation
• Chapter 20 Health Equity and Access: Coverage, Reimbursement, and Patient Navigation
• Chapter 21 Ethics, Consent, and Data Governance in Molecular Oncology
• Chapter 22 Real-World Evidence: Registries, Pragmatic Trials, and Outcomes
• Chapter 23 Decision Algorithms for Common Clinical Scenarios
• Chapter 24 Case Studies: From Tumor Profiling to Therapeutic Impact
• Chapter 25 The Road Ahead: Emerging Modalities and Future Directions

Molecular profiling has transformed oncology from a discipline guided primarily by histology and stage to one increasingly defined by the genetic and immunologic features of a patient’s tumor. As sequencing becomes routine in clinics and hospitals, oncologists and multidisciplinary tumor boards are confronted with a deluge of data: variants of uncertain significance, composite biomarkers like tumor mutational burden, structural rearrangements, and dynamic ctDNA signals that change over time. The promise is tangible—targeted therapies and immunotherapies can deliver profound, sometimes durable responses—but realizing that promise requires a practical, clinically grounded approach to interpreting results and acting on them.

This book was conceived as a hands-on resource for clinicians who must translate genomic reports into treatment decisions. It emphasizes the “how” as much as the “what”: how to choose the right test for the right patient, how to evaluate specimen adequacy, how to recognize technical caveats in bioinformatics pipelines, and how to classify variants using widely accepted actionability frameworks. Equally important, it addresses the interpretive judgment needed to move from a list of alterations to a prioritized plan that considers disease context, line of therapy, prior exposures, toxicity profiles, and patient goals.

We dedicate substantial space to biomarkers that guide both sensitivity and resistance. Clinicians often encounter scenarios where an initially actionable mutation is no longer predictive after exposure to a targeted agent, or where parallel pathways and tumor heterogeneity drive progression. Understanding intrinsic and acquired resistance—through secondary mutations, bypass signaling, phenotypic shift, and microenvironmental factors—helps teams preempt failure, plan rational sequencing, and select combination strategies when appropriate. Liquid biopsy and minimal residual disease testing extend this framework by enabling noninvasive monitoring and earlier detection of molecular progression.

Beyond biology, access matters. Many patients will benefit only if clinicians can navigate coverage hurdles, compassionate use pathways, and trial matching across basket, umbrella, and platform designs. Throughout the book, we provide decision algorithms and practical checklists to streamline these processes, along with templates for tumor board deliberation and documentation. Case studies illustrate the full arc from test ordering to therapy initiation, toxicity management, and outcome assessment, highlighting both successes and pitfalls.

We also confront the ethical and operational dimensions of precision oncology. Somatic testing can unmask germline risk with implications for patients and families, demanding clear consent, thoughtful disclosure, and referral pathways. Data governance, privacy, and equity are not afterthoughts; they are prerequisites for sustainable, trustworthy programs. We discuss strategies to reduce disparities in testing and treatment access, including workflow redesign, patient navigation, and partnerships with payers and community practices.

Finally, cancer genomics is moving quickly. New targeted agents, antibody–drug conjugates, bispecifics, and cell-based therapies are reshaping the landscape, while multi-omic approaches and AI-driven analytics promise to refine prediction and trial design. This book is structured to remain useful amid that change: foundational chapters build durable conceptual frameworks, while later chapters focus on adaptable algorithms and real-world implementation. Our goal is to equip clinicians and tumor boards with the clarity and confidence to move from tumor profiling to truly personalized therapy—safely, effectively, and equitably for every patient who stands to benefit.

Cancer genomics is the study of the complete set of DNA alterations within a tumor, and it has moved rapidly from research laboratories into routine clinical care. At its core is the recognition that each malignancy harbors a unique profile of somatic changes—point mutations, structural rearrangements, copy number shifts—that drive growth and shape treatment response. Precision oncology builds on this by aligning those genomic features with therapies most likely to inhibit the specific pathways involved. In practice, this means turning a molecular report into a therapeutic hypothesis that is tested in the clinic.

Historically, oncology was anchored in histopathology and organ of origin. A patient with non–small cell lung cancer would receive platinum-based chemotherapy, while a patient with metastatic colon cancer would get FOLFOX or FOLFIRI, irrespective of the tumor’s molecular subtleties. This approach delivered real benefits but often left responders and non-responders alike wondering why outcomes varied. The turning point was the recognition that cancers can be addicted to particular signaling pathways, an insight that changed treatment paradigms.

The earliest successes involved targeting single oncogenic drivers. In chronic myeloid leukemia, the discovery of the BCR-ABL fusion led to imatinib, which transformed a once-fatal disease into a manageable condition. In non–small cell lung cancer, EGFR inhibitors produced dramatic tumor shrinkage in patients with activating EGFR mutations, establishing a template for genotype-directed therapy. Similar stories unfolded in melanoma with BRAF inhibitors and in breast cancer with HER2-targeted agents, each demonstrating that matching drug to molecular lesion could improve outcomes.

The modern genomics clinic begins with specimen acquisition and comprehensive profiling. Tumor tissue, obtained via biopsy or resection, is the traditional source of DNA and RNA for sequencing. Increasingly, clinicians also turn to liquid biopsies, circulating tumor DNA extracted from blood, which can provide a minimally invasive snapshot of a tumor’s genome and is especially useful for monitoring changes over time. Ensuring adequate tumor cellularity, preserving nucleic acid quality, and avoiding contamination are practical realities that shape downstream results.

Once a specimen is ready, laboratories apply sequencing technologies tailored to clinical needs. Targeted gene panels offer deep coverage of known oncogenes and tumor suppressors, providing sensitivity for low-frequency mutations in a compact report. Whole exome sequencing examines all protein-coding genes, while whole genome sequencing assesses the entire genome, including non-coding regions and structural variants. RNA sequencing adds insight into gene expression and fusions that may be missed by DNA assays. The choice depends on clinical question, turnaround time, and cost constraints.

The data from these assays pass through bioinformatics pipelines that convert raw sequencing reads into interpretable variants. Quality control steps evaluate metrics like coverage depth, mapping rates, and library complexity, ensuring that the underlying data are reliable. Variant calling identifies differences from the reference genome, and annotation places those changes in biological context, such as the affected gene and predicted protein effect. Understanding these steps helps clinicians recognize technical artifacts and appreciate the limits of detection.

Not all alterations are equal. A central task of the genomics clinic is distinguishing somatic changes—acquired by the tumor—from germline variants inherited from parents. Somatic mutations are the drivers of cancer biology and the primary targets of therapy. Germline findings, such as BRCA1 or BRCA2 mutations, have implications for family members and may open therapeutic avenues like PARP inhibitors. This distinction requires careful interpretation and, at times, confirmatory testing of normal tissue.

Variants are further classified by their likely pathogenicity and clinical actionability. Guidelines from professional societies, including the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists, provide a framework for categorizing variants based on evidence of oncogenicity and therapeutic relevance. In oncology, a tiered system is often used to rank variants from those with strong evidence supporting therapy to those of uncertain significance. Grappling with intermediate categories is part of the daily work of molecular tumor boards.

Actionability depends on context. A BRAF V600E mutation may be highly actionable in melanoma or non–small cell lung cancer, but its significance in colorectal cancer is more complex due to feedback loops that can blunt single-agent BRAF inhibition. The same alteration in different tumor types may have different therapeutic implications, and disease stage and prior therapies can further modulate response. These nuances require clinicians to integrate molecular results with clinical factors like performance status, organ function, and lines of prior therapy.

Targeted therapies aim to inhibit the specific molecules driving tumor growth. Tyrosine kinase inhibitors, monoclonal antibodies, and antibody–drug conjugates are designed to engage proteins implicated in oncogenesis. Some agents, like imatinib, inhibit a single driver; others, like sotorasib targeting KRAS G12C, close a long-standing gap in drugging an “undruggable” target. The rationale for using these agents is grounded in functional evidence, clinical trial results, and the biology of the pathway involved.

Resistance, however, is a constant companion. Tumors evolve under the selective pressure of therapy, acquiring alterations that restore pathway activity or activate parallel signaling. Secondary mutations in the target gene, copy number amplifications, and lineage plasticity are common mechanisms. Recognizing these possibilities guides decisions about switching therapies, combining agents, or re-biopsing to capture the current biology of the disease.

Immune checkpoint inhibitors add another layer of complexity to the genomic clinic. While their approval was initially linked to PD-L1 expression, it became clear that tumor mutational burden and microsatellite instability status also predict response. High mutational loads generate neoantigens that can stimulate T cells, making tumors more visible to the immune system. Integrating these biomarkers with somatic mutations helps identify patients most likely to benefit from immunotherapy.

Liquid biopsy has expanded the toolbox by allowing noninvasive monitoring. Circulating tumor DNA can detect targetable mutations, track response, and uncover emerging resistance without additional invasive procedures. This approach is particularly valuable when tissue is scarce or inaccessible, and it can reveal heterogeneity across multiple metastatic sites. Limitations include lower sensitivity in some settings and challenges in distinguishing tumor-derived DNA from background noise.

Tumor boards play a central role in synthesizing genomic data with clinical realities. A well-run molecular tumor board brings together oncologists, pathologists, genetic counselors, bioinformaticians, and pharmacists to deliberate on test selection, variant interpretation, and treatment selection. Checklists and structured workflows help ensure that key questions are addressed, such as whether the alteration is driver or passenger, whether evidence supports a specific therapy, and whether the patient is eligible for relevant clinical trials.

Clinical trial matching is integral to precision oncology. Basket trials enroll patients across tumor types with a shared molecular alteration, while umbrella trials stratify patients within a single disease by multiple biomarkers. Platform trials evaluate several interventions simultaneously and adapt based on interim results. These designs accelerate learning and provide access to novel agents, but they require efficient workflows and partnerships to identify appropriate studies quickly and to manage consent and logistics.

The ethical and equity dimensions of genomics cannot be overlooked. Informed consent should cover the potential for germline findings, data sharing, and the possibility of uncertain results. Disparities in access to testing and targeted therapies are real, shaped by geography, insurance status, and health system resources. Practical strategies include standardizing testing indications, advocating for coverage, utilizing telemedicine for trial access, and employing patient navigators to help families overcome logistical barriers.

Operationalizing genomics demands attention to turnaround times and test selection. Clinicians must balance the desire for comprehensive profiling with the urgency of starting therapy, especially in aggressive diseases. Reflex testing—ordering a targeted panel at diagnosis alongside standard pathology—can expedite results. If tissue is limited, prioritizing a focused panel that covers the most clinically relevant genes may be the most pragmatic approach.

The biological landscape of cancer is continuously expanding. Beyond single-gene drivers, we now recognize the importance of complex signatures such as homologous recombination deficiency, which sensitizes tumors to PARP inhibition, and the influence of the tumor microenvironment in shaping immunotherapy response. Understanding these broader patterns helps contextualize individual variants and suggests rational combinations, such as pairing DNA damage response inhibitors with immune checkpoint blockade.

Another critical concept is clonal heterogeneity. Tumors are composed of subclones with distinct genomic profiles, and therapy can select for minor clones that were not initially dominant. This explains why a mutation may be detected at low allele frequency early and then emerge as a major driver later. Monitoring techniques, including liquid biopsy, can track these shifts, but interpreting changes in variant allele frequency requires careful clinical correlation.

Precision oncology is not a panacea, and not every patient with a genomic alteration will benefit from a targeted agent. Some drivers are not druggable with current tools; some tumors respond minimally despite pathway inhibition. Conversely, some patients with no clearly actionable mutation may still benefit from immunotherapy based on biomarkers like TMB or MSI. Clinical judgment remains essential, integrating molecular insights with the broader picture of the patient’s disease and goals.

Education is a constant need. Genomic reports can be lengthy and technical, filled with jargon and caveats. Clinicians benefit from learning how to read these documents efficiently: focusing on summary interpretations, checking the evidence tiers, noting any germline recommendations, and understanding the assay’s scope and limitations. Time spent improving genomic literacy pays dividends in patient care and confidence in decision-making.

The cost of testing and therapy is another practical concern. Targeted agents are often expensive, and payers may require documentation of clinical utility and prior authorization. Cost-effectiveness arguments hinge on avoiding ineffective therapy, improving survival, and reducing toxicity. Building a business case involves capturing downstream savings from avoided treatments and hospitalizations, and partnering with hospital administrators and insurers to streamline approvals.

Infrastructure matters as well. A successful genomics program needs reliable pathology workflows, access to sequencing capacity, bioinformatics support, and the ability to store and share data securely. Institutions should establish clear governance for data access and secondary use, with privacy safeguards that meet regulatory requirements. Without these foundational elements, even the best clinical ideas can be thwarted by operational bottlenecks.

Looking ahead, multi-omic approaches promise to refine predictions by integrating DNA, RNA, protein, and epigenetic data. Artificial intelligence tools are being developed to assist with variant interpretation, trial matching, and outcome forecasting. While these advances are exciting, the core principle remains the same: connect the patient’s molecular profile to a therapy that meaningfully alters the course of disease, and do so with safety, efficiency, and compassion.

Cancer genomics is now a core competency of modern oncology. It demands a blend of biological knowledge, technical understanding, and pragmatic clinical reasoning. The chapters that follow break down this competency into actionable components, guiding readers from specimen handling to therapy selection, resistance management, and trial navigation. The aim is to provide a resource that sits on the desk, not the shelf—useful during tumor board, when reading a report, or when facing a patient asking, “What’s next?”